{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:43:37Z","timestamp":1784634217229,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012095","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000}}],"reference-count":75,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012095.pub2","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T11:01:52Z","timestamp":1497006112000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Celecoxib for rheumatoid arthritis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Mahir","family":"Fidahic","sequence":"first","affiliation":[{"name":"University of Tuzla; Medical faculty; Univerzitetska 1 Tuzla Canton Tuzla Bosnia and Herzegovina 75000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Jelicic Kadic","sequence":"additional","affiliation":[{"name":"Cochrane Croatia, University of Split School of Medicine; Soltanska 2 Split Croatia"},{"name":"University Hospital Split; Department of Pediatrics; Spinciceva 1 Split Croatia 21 000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mislav","family":"Radic","sequence":"additional","affiliation":[{"name":"University Hospital Split, School of Medicine, Cochrane Croatia; Division of Rheumatology and Clinical Immunology; \u0160oltanska 2 Split Croatia 21000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Puljak","sequence":"additional","affiliation":[{"name":"University of Split School of Medicine; Cochrane Croatia; Soltanska 2 Split Croatia 21000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"issue":"357","key":"10.1002\/14651858.CD012095.pub2-BIB0001|cit1","first-page":"1","article-title":"Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomised, double-blind, phase III, non-inferiority clinical trial","volume":"15","author":"Choi","year":"2014","journal-title":"BMC Musculosceletal Disorders"},{"issue":"9196","key":"10.1002\/14651858.CD012095.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0004|cit4","first-page":"809","article-title":"Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis","volume":"23","author":"Jaji\u0107","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD012095.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","article-title":"Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis","volume":"19","author":"Kivitz","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"24","key":"10.1002\/14651858.CD012095.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00044011-200424020-00004","article-title":"Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis","volume":"2","author":"Shi","year":"2004","journal-title":"Clinical Drug Investigation"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"20","key":"10.1002\/14651858.CD012095.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD012095.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/1529-0131(200004)13:2<112::AID-ANR5>3.0.CO;2-L","article-title":"Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib","volume":"12","author":"Zhao","year":"2000","journal-title":"Arthritis Care and Research"},{"issue":"26","key":"10.1002\/14651858.CD012095.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","article-title":"Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial","volume":"127","author":"Chan","year":"2004","journal-title":"Gastroenterology"},{"issue":"9573","key":"10.1002\/14651858.CD012095.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","article-title":"Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial","volume":"369","author":"Chan","year":"2007","journal-title":"Lancet"},{"issue":"9736","key":"10.1002\/14651858.CD012095.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","article-title":"Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR):a randomised trial","volume":"376","author":"Chan","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0016-5085(15)30531-X","article-title":"Prevention of recurrent ulcer bleeding in arthritis patients with high cardiovascular and high gastrointestinal risks: an 18-month, double-blind, randomized trial","volume":"148","author":"Chan","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0149-2918(99)80020-4","article-title":"An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs","volume":"21","author":"Cheatum","year":"1999","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012095.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1756-185X.2010.01463.x","article-title":"Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis","volume":"13","author":"Cheung","year":"2010","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1046\/j.1365-2036.2002.01219.x","article-title":"Dyspepsia tolerability from the patients\u2019 perspective: a comparison of celecoxib with diclofenac","volume":"16","author":"Goldstein","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Hegazy R Alashhab M Amin M Cardiorenal effects of newer NSAIDs (celecoxib) versus classic NSAIDs (ibuprofen) in patients with arthritis Journal of Toxicology 2011 10.1155\/2011\/862153","DOI":"10.1155\/2011\/862153"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1185\/03007995.2012.717528","article-title":"Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial","volume":"28","author":"Kellner","year":"2012","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1874312901307010096","article-title":"Celecoxib and diclofenac plus omeprazole are similarly effective in the treatment of arthritis in patients at high GI risk in the CONDOR trial","volume":"7","author":"Kellner","year":"2013","journal-title":"Open Rheumatology Journal"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/gast.2002.36013","article-title":"Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis","volume":"123","author":"Laine","year":"2002","journal-title":"Gastroenterology"},{"issue":"9560","key":"10.1002\/14651858.CD012095.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","article-title":"Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012095.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0254-6272(15)30097-2","article-title":"Effect of Sanhuangwuji powder, anti-rheumatic drugs, and ginger-partitioned acupoint stimulation on the treatment of rheumatoid arthritis with peptic ulcer: a randomized controlled study","volume":"35","author":"Liu","year":"2015","journal-title":"Journal of Traditional Chinese Medicine"},{"issue":"26","key":"10.1002\/14651858.CD012095.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012095.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD012095.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clinthera.2007.05.006","article-title":"Assessment of comparative pain relief and tolerability of SK1306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase lll, noninferiority clinical trial","volume":"29","author":"Song","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD012095.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/annrheumdis-2011-200017","article-title":"Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study","volume":"70","author":"Zayat","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012095.pub2-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006776.pub2","article-title":"Using alternative statistical formats for presenting risks and risk reductions","author":"Akl","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012095.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"7-8","key":"10.1002\/14651858.CD012095.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1345\/aph.10382","article-title":"Upper gastroduodenal ulceration in arthritis patients treated with celecoxib","volume":"35","author":"Ashcroft","year":"2001","journal-title":"Annals of Pharmacotherapy"},{"issue":"8","key":"10.1002\/14651858.CD012095.pub2-BIB0033|cit33","first-page":"1876","article-title":"Uper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen","year":"2000","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0034|cit34","unstructured":"Cates C Dr Chris Cates\u2019 EBM website. Visual Rx Version 3 www.nntonline.net\/visualrx\/"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0035|cit35","unstructured":"Chou R Helfand M Peterson K Dana T Roberts C Drug class review on cyclo-oxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): Final Report Update 3 [Internet] www.ncbi.nlm.nih.gov\/books\/NBK10620\/"},{"issue":"9894","key":"10.1002\/14651858.CD012095.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists' (CNT) Collaboration","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"Conaghan","year":"2012","journal-title":"Rheumatology International"},{"issue":"8","key":"10.1002\/14651858.CD012095.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008322.pub2","article-title":"Non-pharmacological interventions for fatigue in rheumatoid arthritis","author":"Cramp","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012095.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0040|cit40","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0041|cit41","unstructured":"USA Food Drug Administration (FDA) Celebrex product information www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020998s017lbl.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD012095.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/rheumatology\/32.8.724","article-title":"An evaluation of the health assessment questionnaire in long-term longitudinal follow-up of disability in rheumatoid arthritis","volume":"32","author":"Gardiner","year":"1993","journal-title":"British Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012095.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane musculoskeletal group systematic reviews and meta analyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0046|cit46","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"9149","key":"10.1002\/14651858.CD012095.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","article-title":"Cox-2 inhibitors","volume":"353","author":"Hawkey","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0048|cit48","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006853.pub2","article-title":"Dynamic exercise programs (aerobic capacity and\/or muscle strength training) in patients with rheumatoid arthritis","author":"Hurkmans","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7553","key":"10.1002\/14651858.CD012095.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD012095.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","article-title":"Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants","volume":"13","author":"Lanas","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012095.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525.pub2","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Lethaby","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012095.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007356.pub2","article-title":"Rituximab for rheumatoid arthritis","author":"Lopez-Olivo","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD012095.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012095.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar4134","article-title":"Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials","volume":"15","author":"Moore","year":"2013","journal-title":"Arthritis Research and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD012095.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0058|cit58","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD012095.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008922.pub2","article-title":"Muscle relaxants for pain management in rheumatoid arthritis","author":"Richards","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012095.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008921.pub2","article-title":"Neuromodulators for pain management in rheumatoid arthritis","author":"Richards","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012095.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors,methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis:a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD012095.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649.pub3","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0063|cit63","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0064|cit64","unstructured":"Sch\u00fcnemann H Oxman AD Vist GE Higgins JBT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9746","key":"10.1002\/14651858.CD012095.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD012095.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1002\/14651858.CD012095.pub2-BIB0067|cit67","first-page":"247","article-title":"Anti-inflammatory and side effects of cyclooxygenase inhibitors","volume":"59","author":"S\u00fcleyman","year":"2007","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0068|cit68","unstructured":"Therapeutic Goods Administration (Australia) Australian Public Assessment Report for Celecoxib. Proprietary Product Name: Celebrex; Sponsor: Pfizer Australia Pty Ltd; August 2010 www.tga.gov.au\/sites\/default\/files\/auspar-celebrex.pdf"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"British Medical Journal"},{"issue":"66","key":"10.1002\/14651858.CD012095.pub2-BIB0070|cit70","first-page":"1","article-title":"Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis","volume":"17","author":"Walsem","year":"2015","journal-title":"Arthritis Research and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000518.pub2","article-title":"Balneotherapy (or spa therapy) for rheumatoid arthritis","author":"Verhagen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012095.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Vucic K Jelicic Kadic A Puljak L Survey of Cochrane protocols found methods for data extraction from figures not mentioned or unclear Journal of Clinical Epidemiology 2015 1161 4","DOI":"10.1016\/j.jclinepi.2014.11.016"},{"issue":"11","key":"10.1002\/14651858.CD012095.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003113.pub3","article-title":"Opioid therapy for treating rheumatoid arthritis pain","author":"Whittle","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012095.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012095","article-title":"Celecoxib for rheumatoid arthritis","author":"Fidahic","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012095.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003831","article-title":"Celecoxib for rheumatoid arthritis","author":"Garner","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012095.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T07:48:10Z","timestamp":1709624890000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012095.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012095.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}